Xmet-Trio 500/0.2/1 Tablet ER
By Xmet-Trio
Rx
10 Tablet ER in a Strip

Composition
Glimepiride(1mg) + Metformin(500mg) + Voglibose(0.2mg)

Manufacturer - Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals Limited, B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai – 400 026.

Expires on or after
October, 2025

liver
When using Xmet-Trio 500/0.2/1 Tablet ER, it's important to be cautious if you have liver disease. Patients with liver issues may require a dose adjustment when taking this medication. It's recommended to consult your doctor before starting treatment. Typically, Xmet-Trio 500/0.2/1 Tablet ER is initiated at a low dose for individuals with mild to moderate liver disease. However, it is advised not to use this medication in patients with severe liver disease. It's essential to prioritize your liver health and seek guidance from a healthcare professional when considering the use of Xmet-Trio 500/0.2/1 Tablet ER.

kidney
Xmet-Trio 500/0.2/1 Tablet ER may not be safe for patients with kidney disease and should be avoided. Consult your doctor before using. Not recommended for those with severe kidney issues.

alcohol
It is risky to drink alcohol with Xmet-Trio 500/0.2/1 Tablet ER.

driving
When taking Xmet-Trio 500/0.2/1 Tablet ER, avoid driving if experiencing low or high blood sugar symptoms that may affect your focus or reaction time.

pregnancy
Xmet-Trio 500/0.2/1 Tablet ER may be unsafe during pregnancy, as animal studies suggest possible harm to the developing baby. Your doctor will assess potential risks and benefits before prescribing. Please consult your doctor.

breastfeeding
Xmet-Trio 500/0.2/1 Tablet ER may not be safe to use while breastfeeding as it can possibly pass into breastmilk and harm the baby.
Habit Forming | No |
Chemical Class | - |
Therapeutic Class | ANTI DIABETIC |
Action Class | - |
₹115
Inclusive of all taxes
Content verified by

Dr. Abdullah Khan
MBBS - General Medicine
Last update on 01-Oct-2024